Pooled Analysis of Tolerability with Fremanezumab Treatment in Patients with Episodic or Chronic Migraine and Cardiovascular Medication Use at Baseline
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Adverse events (AEs) were evaluated in a subgroup of patients with episodic migraine (EM) or chronic migraine (CM) and CV medication use at baseline in this pooled analysis of phase 3 trials of fremanezumab
- No safety signals were identified, and cardiac and vascular disorder AEs were infrequent across all treatment groups; the most common AEs were injection-site reactions, including pain, erythema, and induration
- Fremanezumab treatment over 12 weeks was well tolerated, with low and similar cardiac and vascular disorder AEs to placebo, in patients with migraine using CV medications at baseline
Presenting Author
Gianluca Coppola, MD, PhD
Clinical Neurologist
Sapienza University of Rome Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies
Rome, Italy
Dr Gianluca Coppola is researcher and clinical neurologist. His Major research interests are neurophysiology and neuroimaging of headaches, migraine in particular, behavioural phenomena of habituation/sensitization, brain plasticity and pain. He personally carried out several experiments using evoked potentials (somatosensory, visual, auditory), transcranial magnetic stimulation, and functional and structural neuroimaging. He is trustee of the International Headache Society (IHS), and secretary of the Italian Society of the Study of Headache (SISC). He is Author or co-Author of several peer-reviewed journal articles and book chapters. He serves as editorial board member and ad-hoc reviewer for several scientific journals.
Author disclosures
Gianluca Coppola, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
